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Abstract
Background: Refined phenotyping of allergic diseases may unravel novel pheno-
types. Conjunctivitis as an independent disorder has never been approached.
Aim: To identify distinct classes of allergic respiratory diseases using latent class
analysis (LCA) and distinguish each class using classification and regression tree
(CART) analysis.
Methods: Seven hundred and twenty‐eight adults from the Portuguese general pop-
ulation study ICAR had a structured medical interview combined with blood collec-
tion, skin prick tests, spirometry with bronchodilation, and exhaled nitric oxide. LCA
was applied to 19 variables. The CART algorithm selected the most likely variables
distinguishing LCA‐classes.
Results: A six‐class model was obtained. Class 1 (25%): nonallergic participants with-
out bronchial or ocular symptoms. Classes 2 (22%) and 3 (11%): nasal and ocular
(low levels) symptoms without nasal impairment, monosensitized (Class 2) or poly-
sensitized (Class 3). Class 4 (13%): polysensitized participants with high levels of
nasal and ocular symptoms, and nasal impairment. Classes 5 (16%) and 6 (14%): high
level of nasal, bronchial and ocular symptoms with nasal impairment (non‐allergic or
polysensitized, respectively). Participants in classes 5 and 6 had more bronchial exac-
erbations and unscheduled medical visits (P < 0.001). Ocular symptoms were signifi-
cantly higher in classes with nasal impairment, compared to those without
impairment (P < 0.001) or no nasal symptom (P < 0.001). CART highlighted ocular
symptoms as the most relevant variable in distinguishing LCA‐classes.
Conclusion: Novel severe phenotypes of participants with co‐occurrence of ocular,
nasal and bronchial symptoms, and exacerbation‐prone were identified. The tree
algorithm showed the importance of the ocular symptoms in the expression of aller-
gic diseases phenotypes.
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1 | INTRODUCTION
Allergic respiratory diseases (ARD) such as asthma, allergic rhinitis, and
conjunctivitis, often co‐exist in the same patient.1 Allergic multimorbid-
ity is independent of Immunoglobulin E (IgE) sensitization,2 but the mul-
timorbid polysensitized phenotype is among the most severe ones.3-5
Multimorbidity is complex and may be difficult to manage in clini-
cal practice.6 Disease stratification using classical diagnostic methods
may not be sufficient for a more effective and personalized patient
care. Identification of “treatable traits” by data‐driven approaches (un-
supervised methods) may be a promising approach7,8 using machine
learning tools.9,10 Previous studies used data‐clustering (unsupervised)
methods, such as latent class analysis (LCA), to identify separately phe-
notypes of asthma,11,12 rhinitis,13,14 and other allergic diseases,15,16
but nasal and ocular symptoms were considered together.16
The LCA seeks to identify homogeneous groups in a heterogeneous
descriptive, a theoretical, and non‐inferential manner without providing
information on the comparative relevance of variables or on the classifi-
cation decision rule.17 The classification and regression tree (CART) anal-
ysis can develop reliable clinical decision rules to be used in the
development of new classification of patients into categories,18,19
because of their easily interpretive nature and ability to handle missing
data.19 The development of a classification tree to classify participants in
the ARD phenotypes, using data readily accessible in most outpatient
settings, is expected to improve patient classification and management.
1.1 | Aim
The present cross‐sectional study aimed to identify distinct classes
of allergic respiratory diseases, in adults from a general population
sample, using latent class analysis and to explore the most relevant
clinical variables that could be used to distinguish each class, using
classification and regression tree analysis. Additionally, we included
ocular symptoms that are usually not considered independently in
allergic multimorbidity but were supported by a study using mobile
technology20 and suggested by MeDALL.16
2 | METHODS
2.1 | Sample and study design
This is a secondary analysis of a national and cross‐sectional study
conducted in the Portuguese general population, ICAR (Control and
Burden of Asthma and Rhinitis) study.21 It comprised anthropometric
measurements, lung function, inflammation and allergy tests, a struc-
tured clinical assessment and standardized questionnaires. Detailed
information is provided in the Online Supplement. ICAR study
enrolled 858 participants, from 3 to 89 years old, with and without
self‐reported asthma and/or rhinitis (Figure S1) and, for this analysis,
we considered all adults (≥18 years old, n = 728) (Table S1).
Ethical approval was obtained from the Hospital Ethics Commit-
tee (Comissão de Ética do Hospital São João, E.P.E) and national
data protection committee (n.12372/2011). All participants gave
written informed consent. The paper follows the STROBE guidelines
for reporting observational studies.22
2.2 | Variables
Demographic characteristics, such as age, gender, body mass index
(BMI), and smoking status were analyzed. Data regarding nasal, bronchial
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GRAPHICAL ABSTRACT
Novel phenotypes of allergic respiratory diseases were identified by latent class analysis, in adults from a general population sample. For the
first time, ocular symptoms were used independently and ranked by classification and regression tree analysis as the most relevant variable to
separate those phenotypes.
and ocular symptoms, bronchial exacerbation and unscheduled medical
visit, in the last 12 months, were collected by clinical interview. Age at
onset of the bronchial symptoms was self‐reported. Further details on
variable definition are described in Online Supplement.
Nasal severity score was adapted from the ARIA severity score,20
and it was calculated using questions regarding impact of nasal symp-
toms on daily activities, work, and sleep, ascribed with the score 1 if
“Yes” and 0 if “No.” The nasal severity score was then categorized as
“no/mild impairment” (ranging 0‐2) and “severe impairment” (score = 3).
Additionally, a diagnosis of rhinitis, asthma, and other allergic dis-
eases was established by an allergy specialist and the use of asthma/
allergy medication in the last 12 months was also analyzed.
2.3 | Measurements
Allergic sensitization (AS) was assessed by skin‐prick tests (SPT), follow-
ing the GA2LEN recommendations.23 The standardized allergen panel
included 28 allergens (Stallergenes Greer®, France),24 categorized into
six groups (mites, dog and cat epitheliums, tree, grass and weed pollens
mixtures, and molds). Monosensitization and polysensitization were
defined, respectively, as sensitization to only one and to two or more
groups of allergens. Furthermore, sensitization data of 25 participants
with current antihistamine medication were considered as missing.
Total immunoglobulin E (IgE), serum eosinophilic cationic protein (S‐
ECP) and blood eosinophilic count (B‐Eos) were obtained from blood
sampling. Phadiatop® (Thermo Fisher Scientific, Uppsala, Sweden) was
used as a screening test; if ≥0.35kU/l the sample was considered as Pha-
diatop‐positive, and additional determinations were performed to assess
individual allergen‐specific IgE (sIgE) antibody concentrations.
Predicted values of basal forced expiratory volume in one second
(FEV1) and bronchodilator response were obtained by spirometry proce-
dure, following the ATS/ERS recommendations.25,26 FEV1 were consid-
ered abnormal if less than the lower limit of normal (LLN).27 Fractional
exhaled Nitric Oxide (FeNO) measurements were performed using NIOX
MINO® (Aerocrine, Solna, Sweden), following the ATS/ERS criteria.28
2.4 | Biases
To reduce the risk of bias, several quality assurance measures were
followed: research assistants performing the evaluations were
blinded to the subject classification at screening; data validity was
periodically verified soon after being collected and custom statistic
algorithms were used to detect extreme, illogical and missing value
and amendments to the protocol were done if necessary.
2.5 | Statistical analyses
Categorical variables are presented as absolute frequencies and pro-
portions. Continuous variables were presented according to their dis-
tributions. The socio‐demographic and clinical variables of the
classes derived from the LCA were described and compared using
chi‐squared test, one‐way analysis of variance and Kruskal‐Wallis
test with Bonferroni correction.
Mplus 6.12 (Los Angeles, CA:Muthén & Muthén) was used to con-
duct LCA analysis and R 3.3.3 (https://www.r-project.org/) to establish
the classification model and build the respective decision tree, using
the “rpart” and “DMwR” packages, respectively. All other analyses
were performed using SPSS Statistics 25.0 (Armonk, NY:IBM Corp)
and P‐values < 0.05 were defined as statistically significant.
2.6 | Unsupervised analysis
LCA was applied to identify underlying unobserved (latent), mutually
exclusive subgroups (classes) based on categorical manifest variables
without the need for historical or a priori assumptions.29 Nineteen
dichotomic variables (defined as “Yes”/”No”) were chosen regarding
nasal, ocular and bronchial symptoms and the 6 groups of AS.
2.7 | Supervised analysis
CART analysis was performed to obtain the classification tree
algorithm, using Gini impurity index and the Cost‐Complexity prun-
ing algorithm.30 The algorithm allows to select the variables most
likely to identify LCA‐classes, which included parameters easily
accessible in most outpatient settings: patient's gender, age, and
BMI; assessment of nasal, bronchial and ocular symptoms, nasal
impairment; and objective diagnostic tests (number of AS groups,
FEV1, and FeNO). The variable importance is given by Gini index
(ranging 0%‐100%).31 Additionally, we randomly divided the data-
set into a training (70%) and a test set (30%) to obtain a reliable
estimate of the model's predictive performance. Cohen's kappa
coefficient (kappa) was used to evaluate model performance for
imbalanced datasets.32
Details regarding LCA and CART methodology and definitions of
each included respiratory/ocular symptoms are provided in Online
Supplement.
3 | RESULTS
3.1 | Sample characteristics
Seven hundred and twenty‐eight adults (63% female) were included,
mean (SD) age of 43.9 (15.2) years, 61% were non‐smokers and 11%
were taking inhaled corticosteroids (ICS). Demographic and clinical
characteristics of the six classes are shown in Table 1.
3.2 | Latent class analysis
A six‐class model was selected as the best solution for these data,
with a significantly better fitting than a five‐class model (P = 0.013),
and a non‐significantly different fit from a seven‐class model
(P = 0.363) (Table S2). Furthermore, entropy of the six‐class model
was 0.873, a good overall certainty in classification.
Figure 1 presents the probability of latent class membership for
each of the six‐class LCA model and Table S3 shows the stratifica-
tion of the LCA‐classes, according to clinical and allergic profiles.
Average posterior probabilities were at least 89% for all classes, indi-
cating a low chance of misclassification.
Two classes were characterized by non‐allergic participants
(>70% with negative SPT): classes 1 (n = 182; 25%) and 5 (n = 114;
16%). Class 1 had very low probability of having respiratory or ocu-
lar symptoms. Class 5 had a very high probability of having nasal,
bronchial, and ocular symptoms with nasal severe impairment (nasal
severity score≥3).
Three classes were predominantly allergic (100% sensitization):
classes 3 (n = 77; 11%), 4 (n = 96; 13%), and 6 (n = 102; 14%). Class
3 had a high probability of nasal and ocular symptoms without sev-
ere nasal impairment (score≤2). Classes 4 and 6 predominantly had
high nasal and ocular symptoms with nasal impairment, differing by
the absence (Class 4) or presence of bronchial symptoms (Class 6).
Class 2 (n = 157; 22%) was characterized by participants with a
very high probability of having nasal symptoms without severe nasal
TABLE 1 Demographics and clinical characteristics of the 6 LCA‐derived classes
Total
(n = 728)
Class 1
(n = 182;
25%)
Class 2
(n = 157;
22%)
Class 3
(n = 77 ;
11%)
Class 4
(n = 102;
14%)
Class 5
(n = 114;
16%)
Class 6
(n = 96;
13%) P‐value
Female, n (%) 461 (63) 105 (58) 89 (57) 45 (58) 65 (64) 95 (83) 62 (65) <0.001*
Age, mean (SD) 43.9 (15.2) 46.9 (16.5) 45.5 (16.4) 39.9 (14.8) 40.3 (12.9) 45.2 (13.4) 41.3 (13.2) <0.001**
BMI, mean (SD) 25.9 (4.7) 26.6 (4.7) 25.1 (4.0) 25.8 (4.3) 25.2 (4.6) 25.8 (5.0) 27.1 (5.3) 0.003**
Age of bronchial
symptoms onset,
median (P25‐P75)
8.0 (3.0‐20.0) 6.0 (1.0‐13.0) 3.0 (2.0‐18.0) 5.0 (3.0‐7.5) 7.0 (2.0‐12.0) 15.0
(3.0‐25.0)
12.0 (4.0‐30.0) 0.06***
Smoking status, n (%)
Non‐smoker 441 (61) 108 (59) 95 (60) 47 (61) 67 (66) 75 (66) 49 (51) 0.01*
Smoker 154 (21) 47 (26) 33 (21) 20 (26) 17 (17) 22 (19) 15 (16)
Ex‐smoker 133 (18) 27 (15) 29 (18) 10 (13) 18 (18) 17 (15) 32 (33)
Packs‐year,
mean (SD)
5.9 (12.8) 8.3 (15.6) 6.5 (14.2) 5.0 (10.6) 3.6 (8.4) 4.2 (8.4) 5.7 (14.0) 0.03**
Current
medication,
n (%)
ICS 81 (11) 3 (2) 6 (4) 14 (18) 5 (5) 18 (16) 35 (36) <0.001*
Number of
AS groups,
median (P25‐P75)
2.0 (0‐6.0) 0 (0‐0.7) 1.0 (0‐2.0) 4.0 (3.0‐5.0) 4.0 (3.0‐5.0) 0 (0‐0) 4.0 (3.0‐6.0) <0.001***
Level of sensitization, n (%)
Monosensitizationa 100 (14) 37 (21) 37 (24) 0 (0) 0 (0) 22 (19) 4 (4) <0.001*
Polysensitizationb 332 (46) 8 (4) 50 (32) 77 (100) 101 (100) 4 (3) 92 (96)
Group of AS, n (%)
Mites 336 (46) 31 (17) 55 (35) 73 (95) 77 (76) 19 (17) 81 (84) <0.001*
Cat and dog
epithelium
220 (30) 2 (1) 18 (11) 64 (83) 60 (59) 7 (6) 69 (72) <0.001*
Molds 135 (19) 0 (0) 11 (7) 33 (43) 40 (40) 1 (1) 50 (52) <0.001*
Pollensc 335 (46) 16 (9) 55 (35) 70 (91) 101 (100) 3 (3) 90 (94) <0.001*
Lung function
FEV1% predicted,
mean (SD)
97.4 (15.5) 99.4 (16.1) 99.6 (13.3) 95.3 (13.9) 98.9 (13.9) 97.2 (15.6) 90.1 (18.4) <0.001**
FEV1 <LLN, n (%) 69 (9) 16 (9) 8 (5) 6 (8) 9 (9) 8 (7) 22 (23) <0.001*
Positive BD, n (%) 55 (8) 11 (6) 5 (3) 7 (9) 4 (4) 12 (11) 16 (17) 0.001*
AS, allergen sensitizations; BD, Bronchodilatation; BMI, body mass index; FEV1, Forced Expiratory Volume in the first second; ICS, inhaled corticos-
teroids; LLN, lower limit of normal; P25‐P75, 25th percentile‐75th percentile.
aSensitization to 1 group of allergens.
bSensitization to 2 or more groups of allergens.
cIncluding tree, grass and weed sensitizations.
*Chi‐squared test.
**One‐way analysis of variance (ANOVA).
***Kruskal‐Wallis test.
impairment, with a moderately increased probability of ocular symp-
toms, and 55% of them were allergic.
3.3 | Latent class characteristics
There were significant differences among the six LCA‐classes in all
variables described in Table 1, except in age of bronchial symptoms
onset (P = 0.06). A female predominance across all classes was
observed, particularly in Class 5 (83%).
Most participants in classes 3, 4, and 6 were polysensitized, with
the more frequent AS groups being: mites, pollens and cat/dog
epithelia (Table 1 and Table S3). Moreover, half of the participants in
Class 2 (n = 87; 55%) were sensitized, particularly to mites (n = 55;
35%) and classes 1 and 5 were mainly non‐allergic.
Regarding the presence of ocular symptoms (Figure 2), the pro-
portion of participants with ocular symptoms is significantly higher in
those with severe nasal impairment (score≥3), compared to those
without nasal impairment (P < 0.001). Similarly, the rate of partici-
pants with ocular symptoms having severe nasal impairment was sig-
nificantly higher when compared to those with mild nasal
impairment (score ≤2) (P < 0.001) or without nasal symptoms
(P < 0.001). Also, among participants without nasal symptoms, the
proportion of ocular symptoms was very low (12%).
Classes 1 and 6 represented two extreme phenotypes: Class 1
was the mildest phenotype, whereas Class 6 was the most severe,
including participants with the lowest and the highest values of B‐
Eos, FeNO and total IgE and proportions of urgent medical care,
respectively (Table 2 and Figure 3). Class 6 participants had signifi-
cantly higher proportions of current use of ICS, abnormal lung func-
tion and positive bronchodilation as compared to other classes
(Table 1). After Class 6, the non‐allergic Class 5 had the second high-
est proportions of participants with current use of ICS (16%), posi-
tive bronchodilation (11%), and bronchial exacerbations, comparing
to other classes.
An “Intermediate” phenotype was found. Class 3 had the lowest
mean age, and when compared to other classes, had significantly higher
proportions of participants with sensitization to indoor allergens, with
18% of them having current ICS medication (Table 1). Participants in
Class 3 had a significantly higher proportion of bronchial exacerbations in
the past 12 months, compared to classes 1 and 2 (P < 0.001) (Figure 3).
Serum total IgE levels and Phadiatop® sIgE were highest in sensi-
tized groups (classes 3, 4, and 6) (Table 2). B‐Eos values were
F IGURE 1 Proportions for the latent classes based on the estimated posterior probabilities [Colour figure can be viewed at wileyonlinelibra
ry.com]
significantly higher in classes 2, 4, and 6 comparing with Class 1.
FeNO values were highest in classes 4 and 6, by comparison to
classes 1, 3, and 5 (P < 0.03) (Figure S2).
Furthermore, medical diagnosis of rhinitis was common in classes
2, 4, 5, and 6 (Table S4), while asthma diagnosis was more frequent in
Class 6 (75%), and less, but also prevalent, in classes 3 and 5 (35% and
31%, respectively). A high proportion of conjunctivitis was diagnosed
in participants belonging to classes 4, 5, and 6. Class 1 participants had
the lowest proportion of diseases medical‐diagnosed, except for the
proportion of other respiratory diseases (20%) (Table S4).
3.4 | CART analysis
Nine terminal nodes were formed in the classification tree (Figure 4),
with a kappa(95% CI) = 0.75(0.72‐0.79). Classification tree showed
that ocular symptoms were the variable with the highest relative con-
tribution to the model (37%), followed by number of AS groups
(21%), having impairment of school/work by nasal symptoms (15%),
presence of bronchial symptoms (13%), having impairment of daily
activities (12%) and sleep disturbance due to nasal symptoms (3%).
On the right side of the tree (corresponding to participants sensi-
tized to ≥3 AS groups), the presence of bronchial symptoms, distin-
guished Class 6 from all the others. When bronchial symptoms were
absent, the presence/absence of impairment in daily activities and
sleep disturbance by nasal symptoms, differentiated classes 3 and 4.
Using a training (n = 509) and a test set (n = 219), the obtained
CART algorithm was identical (Figure S3) and similar kappa was also
obtained (0.73[0.67‐0.80]).
4 | DISCUSSION
We identified from a general population sample using an unsuper-
vised method six distinct classes of ARD in adults having clinically
relevant differences in disease profiles. This study identified classes
not determined by a clinical organ‐centered diagnosis, but rather
clinical characteristics and allergy profiles focusing on allergic
multimorbidities. There were two non‐allergic ARD phenotypes
(classes 1 and 5), three allergic phenotypes (classes 3, 4, and 6), and
one with half of the participants being allergic (Class 2). Moreover,
we identified novel severe ARD phenotypes, with participants having
concomitant ocular, nasal and bronchial symptoms (classes 5 and 6)
who are prone to exacerbations. CART analysis ranked ocular symp-
toms as the most relevant variable to separate LCA‐classes, among
respiratory symptoms, nasal‐related impairment and diagnostic tests
readily accessible in most outpatient settings.
4.1 | Strengths and limitations of the study
Limitations of this study should be recognized. The most important
is that this work lacks external validity, and therefore generalizabil-
ity. A potential source of bias for unsupervised analysis is how indi-
viduals were included. In our study, this risk is very low because not
only we included data in LCA that was obtained in the clinical
assessment rather than data from the initial screening (self‐
reported), but also, more importantly, pre‐screening did not com-
prise data regarding ocular symptoms. Although we included partici-
pants from all regions of mainland Portugal, the sensitization profile
to some allergens vary in Europe and results might differ depending
on geographic areas. The choice of clinical variables included in the
unsupervised model may condition the obtained LCA‐classes. How-
ever, their inclusion was justified not only by their clinical relevance,
being currently used and validated questions comprehending the
main dimensions of the ARDs,1,33,34 but also compensating the fact
that a high number of variables potentially increases the risk of
some domains allocate too much weight in the modelling process.17
The inclusion of diagnostic tests was based on parameters being
easily accessible at a visit to a specialist in clinical practice and that
could prove useful in disease stratification and management. A sen-
sitivity analysis was conducted using multiple imputation of incom-
plete data35 and the obtained LCA‐classes were similar when
imputing all missing values (data not shown). Finally, the cross‐sec-
tional design of this study does not allow us to address latent
classes stability over time.
F IGURE 2 Proportions of participants with ocular symptoms, stratified by (A) the presence of nasal‐related impairment and (B) ARIA
severity score. The presence of nasal‐related impairment defined as at least one of the following questions: impairment of daily activities by
nasal symptoms, impairment of school/work by nasal symptoms and/or disturbed sleep due to nasal symptoms
The unsupervised analysis based on airways symptoms and allergy
profile data remains a powerful approach toward ARD phenotyp-
ing.10,16,36 In our study, we not only identified data‐driven phenotypes
but also, we provided information on the relevance of the variables
that better distinguish the LCA‐classes, using the supervised method
CART analysis. While some previous studies used only unsupervised‐
clustering methods to identify phenotypes of ARD,11-14 the present
study extended this approach into providing information on the impor-
tance of the variables that best distinguish between the obtained
classes, using CART analysis. To our knowledge, this is the first time
CART analysis is studied in a population‐based study of ARD. This
analysis has various advantages over other methods, including multi-
variable logistic regression: it is a nonparametric method; results are
summarized in a tree, much simpler to interpret and more practical in a
clinical setting; and measures the variable relevance in the model (rela-
tive impact of the predictors on the output).31 Also, our tree algorithm
based on parameters already used in clinical practice performed well
using a training and a test set, suggesting a high potential to be further
applied.
A major strength of the study is that we used ocular symptoms
independently for the first time in LCA and they were found to be
extremely informative.
4.2 | Interpretation of the results
4.2.1 | Profiles differed by their association with
IgE allergy
There were two non‐allergic ARD phenotypes (classes 1 and 5),
three allergic phenotypes (classes 3, 4, and 6) and one with 50% par-
ticipants being allergic (Class 2). Class 1 was the mildest phenotype,
without symptoms or inflammation. Class 5 comprised predominantly
females, with low FeNO and B‐Eos, and a high proportion of urgent
health care use, suggesting that bronchial symptoms can be linked
with non‐allergic rhinitis37 or rhinosinusitis. Moreover, Class 5 partic-
ipants have some characteristics similar to the non‐allergic rhinitis
phenotype obtained by cluster analysis in other studies.13,14
4.2.2 | Multimorbidity is a necessary component of
ARD
In our study, the unsupervised analysis did not identify clusters of partici-
pants having asthma/rhinitis/conjunctivitis only, supporting the concept
of “one airway one disease”38 and considering the view that rhinitis, con-
junctivitis, and asthma are different manifestations of the same disease.
Particularly, there was no asthma cluster without rhinitis. This accords
with epidemiologic studies such as ECRHS where asthma alone repre-
sents <10% of the asthmatic population. Thus, it seems that in clinical
practice, multimorbidity should always be investigated in ARD patients.
This fact also holds for a precision medicine approach based on treatable
traits, rather than diagnostic labels, in the clinical management of the
ARDs.1,8,39 One surprising issue is the prevalence of conjunctivitis in four
classes. However, the diagnosis was made by a physician.T
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The obtained LCA‐classes found in our sample, derived from the
general population, were very similar to previously published clinical
phenotypes in non‐allergic and allergic rhinoconjunctivitis patients.40,41
However, we not only reinforced the different patterns of multimorbid-
ity in participants with rhinitis, but also, we identified a specific class of
participants polysensitized predominantly to indoor allergens (Class 3),
with mild nose and ocular symptoms but presenting bronchial exacerba-
tions, suggesting that different phenotypes of ARD can be obtained
when analyzing a more comprehensive sample (population‐based) and
not derived from a secondary healthcare setting.
4.2.3 | Ocular symptoms are essential to identify
clusters of ARD patients
The inclusion of ocular symptoms, independently from other symptoms
was not explored in cluster analyses except by MeDALL,16 but, in this
study, only rhinoconjunctivitis was considered. We observed that the
proportion of ocular symptoms was significantly higher in participants
with severe ARD (Classes 3 and 4 [severe nasal disease], 5 and 6 [severe
nasal and bronchial disease prone to exacerbations]) and were less
expressed in participants with milder ARD (classes 2 and 3). Finally, it
F IGURE 3 Proportions of participants
with bronchial exacerbations and
unscheduled medical visits, stratified by
LCA‐classes
Class 1 
182/0/0/0/0/0
Class 2 
0/115/4/4/10/0
Class 2
0/10/4/0/0/8
Impairment of  
school/work by 
nasal symptoms 
Ocular symptoms
Class 5 
0/21/0/0/36/3
Class 5 
0/0/0/4/68/6
Bronchial symptoms
Class 6 
0/1/23/24/0/78
Class 4 
0/0/0/39/0/0
Class 4 
0/2/4/14/0/0
Class 3
0/9/42/17/0/0
Bronchial symptoms
N
N Y
Y
N Y
Nº of allergens groups 
sensizaons ≥3
N Y
N
YN
YN
N Y
Sleep disturbance due 
to nasal symptoms
No of allergens groups 
sensizaons ≥2
Impairment of  
daily acvies by 
nasal symptoms
Y
A
C
C
C
B
B
D
D
F IGURE 4 Classification tree algorithm generated by CART analysis using easily accessible parameters available in the clinical setting. (A) At
least 1 ocular symptom: Watery eyes and/or Itchy eyes. (B) Mites, Cat/dog epitheliums, Tree, Grass, Weed, Molds. (C) Impairment due to nasal
symptoms: Sneezing, Rhinorrhea, Nasal pruritus, Nasal congestion; (D) At least one bronchial symptom: Dyspnea, Dyspnea at night, Wheezing
and/or Chest tightness. N: No; Y: Yes [Colour figure can be viewed at wileyonlinelibrary.com]
was found that ocular symptoms are associated with the severity of
nasal symptoms suggesting that rhinitis and rhinoconjunctivitis repre-
sent two distinct phenotypes. This accords with a paper showing that
the number of allergens recognized in the two phenotypes differ (low
number in rhinitis, significantly higher number for rhinoconjunctivitis,
Siroux et al, submitted).
The polysensitized multimorbid phenotype (Class 6) proposed by
MeDALL4,5 was confirmed and found to be associated with rhinitis
and asthma severity. Moreover, this study also identified conjunctivi-
tis as another component of the multimorbid ARD phenotype. This
class has some characteristics similar to those found in other unsu-
pervised clustering studies, which has labeled as “late‐onset, inflam-
mation predominant”.11,12,42
4.2.4 | CART analysis ranked ocular symptoms as
the most relevant variable to separate LCA‐classes
The tree algorithm not only reinforced the importance of including
the presence of ocular symptoms in the expression of ARD pheno-
types, among other easily accessible parameters used in a routine
clinical practice, but also it may help to classify patients in clinical
settings and to distinguish between lower or higher degrees of air-
ways allergic multimorbidity.
4.2.5 | This study has an important impact in
epidemiology
The concept of the importance of ocular symptoms in allergic multi-
morbidity was raised by a big data study using an App in uncharac-
terized users.43 This hypothesis‐generating study needed to be
confirmed by a classical epidemiologic study and the present study is
the first to show the relevance of big data in the future of epidemi-
ology for respiratory and allergic diseases.
4.2.6 | The characterization of airway inflammation
in ARD is also essential44
In our data, we observed that B‐Eos values were lower in participants of
class 1, separated those with and without nasal and ocular symptoms,
and lower FeNO values in non‐allergic participants and without nasal‐
related impairment, differentiating phenotypes with different allergy pro-
files and symptoms severity, supporting the view that the combination
of these two biomarkers should be used for personalized treatment.45,46
4.3 | Generalizability
This study performed in Portugal needs to be confirmed in other
countries as regional variations exist in allergens. However, a study
on multimorbidity and allergen sensitizations showed that similar
data were observed in France and Sweden suggesting common bio-
logical mechanisms.47 After validation of these phenotypes in other
populations, further work should address biologic associations, such
as total IgE, sIgE, B‐Eos, S‐ECP, and mechanisms within these
phenotypes. Also, studies on the differentiation of allergic vs non‐
allergic conjunctivitis, and regarding symptoms’ deterioration among
non‐smokers vs smoker/former‐smokers and among different sensiti-
zations, should be done, especially with prospective designs.
5 | CONCLUSION
The findings of our study challenge the conventional disease clas-
sification of a “classical” clinical diagnosis organ‐based approach, to
a combination of unsupervised and supervised analysis bringing
novel insights to phenotyping ARD while helping confirm and inte-
grate phenotypes previously reported. Six latent classes of ARD
were identified in adults from a general population sample, with
clinically relevant differences in disease profiles. Novel severe phe-
notypes of participants with co‐occurrence of ocular, nasal and
bronchial symptoms and exacerbation‐prone, were revealed. Fur-
thermore, the tree algorithm not only reinforced the importance
of ocular symptoms in the expression of ARD phenotypes but also
may help to distinguish between lower and higher degree of aller-
gic airway multimorbidity.
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